Relief for Teva as longer-lasting Copaxone gets US nod
This article was originally published in Scrip
The US FDA has approved Teva Pharmaceuticals' supplemental new drug application (sNDA) for three-times-a-week Copaxone (40mg injection). Teva has a lot riding on the new formulation of the multiple sclerosis drug, with the first patent expiries of the old Copaxone (20mg daily injection) coming in May this year. Teva had Copaxone revenues in excess of $4bn last year.